**Addional file 8. Table S7**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **CJD + AD group n=24, (%)** | **Control group n=24, (%)** | **p** |
| **Total disease duration** – Mean ± SD | 4.4 ± 2.1 | 4.6 ± 3.0 | 0.828 |
| **Symptom(s) at onset*** Cognitive
* Cerebellar
* Visual
* Behavioral
* Others
 | 13 (54.2)6 (25.0)5 (20.8)5 (20.8)0 (0.0) | 8 (33.3)10 (41.7)8 (33.3)5 (20.8)4 (16.7) | 0.2440.3580.5160.722 |
| **PSWC/tested at EEG** | 17/23 (73.9) | 17/24 (70.8) | 0.928 |
| **Positive/tested brain MRI\*** | 7/10 (70.0) | 10/13 (76.9) | 0.917 |
| **Positive/tested surrogate CSF biomarkers of neurodegeneration** | 15/17 (88.2) | 19/20 (95.0) | 0.833 |
| **CSF Aβ42** (pg/ml)  | 310(294-451)[n=11] | 641(360-834.5) [n=9] | 0.015 |
| **CSF Aβ40** (pg/ml) | 6089(4433.5-6653.5) [n=9] | 5477 (2269.5-8920.5) [n=9] | 0.860 |
| **CSF Aβ42/Aβ40x10** | 0.746(0.466-0.840) [n=9] | 1.17 (0.940-1.790) [n=8] | 0.003 |